Buy Rating Affirmed for Alumis Inc. on Strong Prospects for TYK2 Inhibitor ESK-001
Cantor Fitzgerald Initiates Alumis(ALMS.US) With Buy Rating, Announces Target Price $13
Guggenheim Initiates Alumis at Buy With $32 Price Target
Alumis Price Target Announced at $29.00/Share by Leerink Partners
Alumis Analyst Ratings
No Data